Nuvalent Appoints Christy Oliger to Board of Directors

Rhea-AI Summary

Nuvalent (NUVL) has appointed Christy Oliger to its Board of Directors, strengthening its leadership team as the company approaches potential commercialization. Oliger brings over 30 years of pharmaceutical and biotech industry experience, most notably serving as Senior Vice President of the Oncology Business Unit at Genentech. During her 20-year tenure at Genentech, she held various senior leadership roles across multiple therapeutic areas including oncology, neurology, rare disease, and immunology. The appointment comes as Nuvalent prepares for a potential first approval from its pipeline of novel kinase inhibitors in 2026. The company, focused on developing targeted cancer therapies, aims to leverage Oliger's commercial expertise in delivering new treatments to patients.

Positive

• Addition of seasoned executive with 30+ years of pharmaceutical and biotech experience
• Strategic timing of appointment ahead of potential first drug approval in 2026
• Strengthened commercial expertise through Oliger's experience as SVP of Genentech's Oncology Business Unit

Negative

• None.

CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christy Oliger to its Board of Directors.

"Christy's proven success in delivering new therapies to patients living with cancer strengthens our Board as we evolve from a development-stage company toward potential commercialization," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "We welcome her deep expertise and valuable perspective to our team as we prepare for a potential first approval from our pipeline of novel kinase inhibitors in 2026."

Ms. Oliger brings more than 30 years of commercial and business experience in the pharmaceutical and biotechnology industry to the Nuvalent Board. Most recently, Ms. Oliger served as Senior Vice President of the Oncology Business Unit at Genentech, where she was responsible for all commercial activities in the U.S. During her 20-year tenure at Genentech, Ms. Oliger held a number of senior leadership roles in both commercial and research and development across a variety of therapeutic areas, including oncology, neurology, rare disease, respiratory, dermatology and immunology. Prior to Genentech, she held management positions at Schering-Plough.

"Nuvalent's pipeline reflects a focused and disciplined approach to drug development, grounded in rigorous science and a deep understanding of patient and physician needs," said Ms. Oliger. "I believe in the potential of these programs to make a meaningful difference, and look forward to supporting this dedicated team towards achieving its goal of delivering a new generation of precisely targeted therapies to the patients who need them."

About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Nuvalent's strategy, business plans, and focus; the expected timing of potential product approvals; the potential of Nuvalent's pipeline programs; Nuvalent's potential commercialization of its product candidates, if approved; Nuvalent's research and development programs for the treatment of cancer; and risks and uncertainties associated with drug development. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "aim," "goal," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented.

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: risks that Nuvalent may not fully enroll its clinical trials or that enrollment will take longer than expected; unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies and clinical trials; the risk that preliminary results of clinical trials may not be predictive of future results from the same or other trials; the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials; the risk that data from our clinical trials may not be sufficient to support registration and that Nuvalent may be required to conduct one or more additional studies or trials prior to seeking registration of our product candidates; the occurrence of adverse safety events; risks that the FDA may not approve our potential products on the timelines we expect, or at all; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its discovery programs; the direct or indirect impact of public health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent's clinical trials, strategy, and future operations; the timing and outcome of Nuvalent's planned interactions with regulatory authorities; and risks related to obtaining, maintaining, and protecting Nuvalent's intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Nuvalent's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as any prior and subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Nuvalent's views only as of today and should not be relied upon as representing its views as of any subsequent date. Nuvalent explicitly disclaims any obligation to update any forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-appoints-christy-oliger-to-board-of-directors-302485674.html

SOURCE Nuvalent, Inc.

FAQ

Who is Christy Oliger and why did Nuvalent (NUVL) appoint her to the board?

Christy Oliger is a pharmaceutical industry veteran with over 30 years of experience, most recently serving as SVP of Genentech's Oncology Business Unit. Nuvalent appointed her to strengthen their board as they prepare for potential commercialization of their first drug in 2026.

When does Nuvalent (NUVL) expect its first drug approval?

Nuvalent is preparing for a potential first approval from their pipeline of novel kinase inhibitors in 2026.

What was Christy Oliger's role at Genentech?

At Genentech, Christy Oliger served as Senior Vice President of the Oncology Business Unit, managing all U.S. commercial activities. During her 20-year tenure, she held various senior leadership roles in commercial and R&D across multiple therapeutic areas.

What type of company is Nuvalent (NUVL)?

Nuvalent is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for clinically proven kinase targets in cancer.

What therapeutic areas does Nuvalent (NUVL) focus on?

Nuvalent focuses on creating precisely targeted therapies for clinically proven kinase targets in cancer treatment.